Henry Hagopian III - 29 Aug 2022 Form 4 Insider Report for Annovis Bio, Inc. (ANVS)

Role
Chief Financial Officer
Signature
/s/ Henry Hagopian, III
Issuer symbol
ANVS
Transactions as of
29 Aug 2022
Net transactions value
$0
Form type
4
Filing time
31 Aug 2022, 20:14:11 UTC
Next filing
20 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANVS Stock Option (right to buy) Award $0 +120,000 $0.000000 120,000 29 Aug 2022 Common Stock 120,000 $11.55 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests one-third on August 29, 2023 and the remaining two-thirds will vest in eight consecutive quarterly installments beginning the fifteenth month after August 29, 2022, and will vest in full upon a Change of Control (as defined in the Company's 2019 Equity Incentive Plan), with vesting conditioned on continued employment on the applicable vesting dates.